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Abstract
The blood-retinal barrier (BRB) prevents most systemically-administered drugs from reaching the retina. This study
investigated whether burst ultrasound applied with a circulating microbubble agent can disrupt the BRB, providing a
noninvasive method for the targeted delivery of systemically administered drugs to the retina. To demonstrate the efficacy
and reversibility of such a procedure, five overlapping targets around the optic nerve head were sonicated through the
cornea and lens in 20 healthy male Sprague-Dawley rats using a 690 kHz focused ultrasound transducer. For BRB disruption,
10 ms bursts were applied at 1 Hz for 60 s with different peak rarefactional pressure amplitudes (0.81, 0.88 and 1.1 MPa).
Each sonication was combined with an IV injection of a microbubble ultrasound contrast agent (Definity). To evaluate BRB
disruption, an MRI contrast agent (Magnevist) was injected IV immediately after the last sonication, and serial T1-weighted
MR images were acquired up to 30 minutes. MRI contrast enhancement into the vitreous humor near targeted area was
observed for all tested pressure amplitudes, with more signal enhancement evident at the highest pressure amplitude. At
0.81 MPa, BRB disruption was not detected 3 h post sonication, after an additional MRI contrast injection. A day after
sonication, the eyes were processed for histology of the retina. At the two lower exposure levels (0.81 and 0.88 MPa), most
of the sonicated regions were indistinguishable from the control eyes, although a few tiny clusters of extravasated
erythrocytes (petechaie) were observed. More severe retinal damage was observed at 1.1 MPa. These results demonstrate
that focused ultrasound and microbubbles can offer a noninvasive and targeted means to transiently disrupt the BRB for
ocular drug delivery.
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Introduction
Delivering pharmaceutical agents to specific retinal locations
may greatly improve treatment of degenerative retinopathies,
including age-related macular degeneration, diabetic retinopathy,
and hereditary retinal disorders such as Norrie disease. However,
delivery of most therapeutic agents to the retina from the
peripheral circulation is limited by the membrane impermeability
of blood-retinal barrier (BRB) [1], which is formed by complex
tight junctions of the endothelium of retinal blood vessels and the
retinal pigment epithelium [2]. The BRB also presents a functional
impediment for drug delivery due to efflux transporters such as P-
glycoprotein [3] that rapidly eliminate many substances from the
extravascular space. Currently an estimated 98% of clinically
validated drugs, of which many are potential therapies for retinal
diseases, cannot cross the BRB [4,5,6,7].
Multiple methods, including topical, systemic, periocular, and
intravitreal approaches, are currently used to deliver drugs to the
eye [8]. If the retina is the target, topical, systemic and periocular
approaches are limited due to the presence of the BRB and other
ocular barriers. Intravitreal injections can effectively deliver drugs
to the fundus, but this is an unpleasant, invasive procedure with
risk of retinal detachment, retinal hemorrhage, endophthalmitis
and glaucoma [9,10]. For chronic diseases requiring repeated
intraocular injections, the risks multiply. In some cases, intravitreal
approaches may also not be able to deliver sufficient drug to the
retina due to the inner limiting membrane (the border between the
vitreous humor and the retina) [11]. Hence, the development of
minimally-invasive and efficient techniques to bypass the BRB and
allow passage of otherwise non-permeable therapeutic agents to
the retinal tissue is desired.
A decade ago, a noninvasive, targeted, and reversible technique
that combines low-energy ultrasound bursts with IV-administered
microbubble ultrasound contrast agent to temporarily induce
blood-brain barrier (BBB) disruption was found [12]. The
technique has been shown to induce blood-brain barrier
disruption without other significant side effects [13,14,15], to
deliver even large-molecular drugs [16], and to improve thera-
peutic outcomes in animal disease models [17,18]. This technique
can also increase delivery of anti-cancer agents to tumors which
have pathological blood vessels that lack a fully-intact BBB [17].
Importantly, the barrier is restored a few hours after sonication
[12,19,20], providing a time window sufficiently long for drug
delivery but short enough to escape the toxic effects of long-term
BBB disruption.
The mechanisms that result in BBB disruption using this
technique have not been fully elucidated. It does not appear to be
the result of violent microbubble collapse (i.e., inertial cavitation)
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microscopic data indicate that the disruption is not caused by
permanent vessel damage (i.e. tears or rupture), but instead it
appears to be caused by the mechanical stimulation that induces a
temporary widening of tight junctions [20] and results in active
transport [21] that allows drugs to be delivered to the brain. There
are several microbubble dynamics activated by an ultrasound
pressure field that will create forces on the vasculature, including
acoustic radiation force on the microbubbles, bubble oscillation,
and acoustic streaming [21]. These forces may induce direct
physical changes to the endothelium, or they could potentially
evoke biological changes such as calcium concentration changes
[22,23] or Akt activation [24], which could induce the BBB
disruption. Ultrasound and microbubble interactions can also
generate transient pores in cell membranes (i.e, sonoporation), a
process thought to be due to shear stress induced by acoustic
streaming [25] or other forces induced the microbubble dynamics.
Whether such pores are created in the endothelial cells during
sonications that produce BBB disruption, and their role in the
disruption process are not known.
The retina and several other organs of the body also have
vascular barriers similar to the BBB that restrict passage of
systemically-administered substances. The mechanical stimulation
on the blood vessels provided by the ultrasound exposures and the
microbubbles might be expected to produce similar changes to
barrier function in these structures. For example, the filtration rate
in the kidney can be temporarily increased using the same
technique, presumably through disruption of the ‘‘blood-urine
barrier’’ [26].
In this study, we investigated in rats whether exposure by an
ultrasound field in the presence of a circulating microbubble agent
can induce a transient increase of retina vascular permeability for
ocular drug delivery. MRI was used to guide the procedure, and
the BRB disruption was verified through the delivery of an MRI
contrast agent that normally does not reach the retina.
Materials and Methods
Animals
All experimental procedures were approved by the Animal Care
Use Committee of Harvard medical school (Protocol 02674).
Twenty male Sprague-Dawley rats (Charles River Laboratories,
Boston, MA; weighing: 300–450 g) were used for this study.
Sixteen animals were sonicated; four served as controls (Table 1).
Before sonications, the animals were anesthetised with a mix of
80 mg/kg of ketamine (Aveco Co., Inc., Fort Dodge, IA) and
10 mg/kg of xylazine (Lloyd Laboratories, Shenandoah, IA) by IP
injection. The hair around the eye was removed with clippers and
depilatory cream (Nair, Church & Dwight Co., Inc., Princeton,
NJ), and a catheter was placed in the tail vein. Body temperature
was maintained throughout the procedure with a heated water
pad.
Equipment
The ultrasound system and experimental setup were the same as
used previously for BBB disruption in small animals [19]. The
ultrasound field was generated using a custom-designed, single-
element, spherically curved, air-backed transducer with a diameter
of 100 mm and radius of curvature of 80 mm operating at a
frequency of 690 kHz. The absolute and relative peak negative
pressure amplitudes were measured in a water tank with a
calibrated 0.5 mm diameter membrane hydrophone (Marconi,
Chelmsford, UK). Reported exposure levels are peak rarefactional
focal pressure (PRFP) amplitudes measured in water. The PRFP
amplitude at the retina after transmission through the lens can be
estimated by multiplying these values by a factor of 0.96, based on
an attenuation coefficient and thickness of the lens of 1.4 dB/cm/
MHz [27] and 3.5–4.0 mm, respectively. The attenuation of the
other components of the rat eye (cornea, iris, vitreous) is negligible
at this frequency. The pressure distribution of the transducer was
mapped using a 0.2 mm needle hydrophone (Onda, Sunnyvale,
CA) and a computer-controlled positioning system (step size:
0.25 mm). The half-maximum diameter and length of the focal
pressure distribution were 2.3 and 12 mm, respectively.
The transducer was immersed in a tank of degassed water and
mounted in a manually-operated, MR-compatible positioning
system. Experiments were performed in a clinical 3 T MRI
scanner (General Electric Healthcare, Milwaukee, WI). MRI was
used for image guidance and evaluation of BRB disruption.
Imaging was performed using a 7.5 cm diameter transmit/receive
surface coil (constructed in-house). The experimental setup is
diagrammed in Fig. 1A. Fig. 1B shows an MR image of the system
with the ultrasound beam path superimposed. The inset in Fig. 1B
shows the normalized pressure distribution in the focal region of
ultrasound beam (boxed region drawn around the eye) at the same
scale as the MR image. Relevant anatomical features in this image
are noted in Fig. 1C.
The transducer was driven by a signal generated by an arbitrary
waveform generator (Model 395, Wavetek Inc., San Diego, CA)
and an RF amplifier (Model 240L, ENI Inc., Rochester, NY). The
electrical impedance of the transducer was matched to the output
impedance of the amplifier using an external inductor-capacitor
tuning network. The electrical power was monitored with a power
meter (Model E4419B, Agilent, Santa Clara, CA) and dual-
directional coupler (Werlatone, Patterson, NY). The transducer
efficiency was measured with a radiation force balance consisting
of an absorbing brush attached to a digital scale.
Sonications
Burst sonications (10 ms bursts applied at 1 Hz for 60 s) at
PRFP amplitudes of 0.81, 0.88, and 1.1 MPa were delivered
through the cornea and lens onto the retina in one eye of each rat,
which laid in the lateral decubitus position on the sonication
system (Fig. 1A). The eye was coupled to the tank containing the
focused ultrasound (FUS) transducer via a bag of degassed water.
Five overlapping locations at the fundus of one eye in each
animal were sonicated at the same PRFP amplitude. One target
was centered on the optic nerve head; the others were at locations
61.5 mm away in the left/right and anterior/posterior directions.
Three of the target locations are indicated by star symbols in
Fig. 1C. Each sonication was applied 10 s after an IV bolus
injection of ultrasound contrast agent (USCA) microbubble
suspension (Definity, Lantheus Medical Imaging, N. Billerica,
MA). Immediately after ‘‘activation’’ of this agent, the suspension
contains approximately 1.2610
10 lipid-shelled microbubbles/mL
with mean diameter range of 1.1 mm–3.3 mm. For the current
study, the solution was diluted 10 times in PBS and was injected
IV at dosage of 20 ml/kg, which is approximately double the
recommended dose for clinical use with ultrasound imaging. The
administration of Definity was followed by an injection of 0.2 mL
normal saline (0.9% NaCl) to flush the agent from the catheter in
the tail vein. Sonications of the individual locations were spaced at
least 2 min apart to allow the agent to mostly clear from the blood
vasculature.
Magnetic resonance imaging
MRI procedures were similar to those described previously for
BBB investigations in small animals [19]. Before the rat
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coordinate-space was visualized by imaging temperature changes
induced in a silicone phantom with a T1-weighted fast spin echo
(FSE) sequence. Then, the animal was placed on the sonication
system. T2-weighted FSE images (Repetition time (TR): 2000 ms,
echo time (TE): 85 ms, echo train length (ETL): 8, number of
excitations/averages (NEX): 2) was used to select the targets. After
sonication, serial contrast- enhanced T1-weighted FSE images
(TR/TE: 500/17 ms, ETL: 4, NEX: 4) were acquired every 5 min
up to 30 min to visualize the BRB disruption. These images were
acquired before and after an IV injection of the MRI contrast
agent Gadopentetate dimeglumine (Gd-DTPA) (Magnevist, Berlex
Laboratories, Inc., Wayne, NJ, USA; molecular weight: 938 Da)
administered as a bolus at a dose of 0.125 mmol/kg. In four
animals, the contrast-enhanced imaging was repeated with the
second Gd-DTPA injection 3 or 3.5 h after sonication (Table 1).
The T2- and T1-weighted FSE images were obtained with an
8 cm field of view, a matrix size of 2566256, and a slice thickness
of 1 mm.
Histology
The animals were sacrificed 24 h after the last sonication. Each
animal was deeply anesthetized, sacrificed, and its eye fixed via
transcardial perfusion (0.9% NaCl, 100 mL; 10% buffered
formalin phosphate, 250 mL). A representative example from
each experimental group (Table 1) was examined in light
microscopy. For this examination, the eye was embedded in
paraffin and serially sectioned at 5 mm in the coronal plane
(parallel to the direction of ultrasound beam propagation). Every
50
th section (250 mm apart) was stained with haematoxylin and
eosin (H&E). Three sonicated and one non-sonicated (control) eyes
were examined. The author (NV) who evaluated the histology was
blind to the FUS exposure parameters.
Table 1. Summary of the experimental groups.
Pressures amplitude (MPa) Number of rats/BRBD* Number of rats for BRB recovery Number of rats for histology
1.1 6/6 1
a 1
0.88 4/4 0 1
0.81 6/6 3
b 1
0 (Control) 4/0 0 1
Total rats 20/16 4 4
For blood-retinal barrier (BRB) recovery study, the second Gd-DPTA injection was administered 3.5h
a or 3h
b after the last sonication.
*BRBD: blood-retinal barrier disruption.
doi:10.1371/journal.pone.0042754.t001
Figure 1. BRB disruption in the rat eye using an MRI-guided FUS system. (A) Schematic diagram of the experimental set up used to disrupt
the BRB. (B) Coronal T2-weighted MR image of a rat eye within the sonication system. The eye was partially submerged in water to allow for acoustic
coupling. The ultrasound beam path is superimposed. (Inset) Normalized focal pressure distribution of the focal region of the ultrasound beam
(boxed region) displayed at the same scale as the MR image. (C) Relevant anatomical features of the eye visible in the MR image. The location of three
of the five locations targeted for sonication are shown as star symbols.
doi:10.1371/journal.pone.0042754.g001
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MR image analysis was performed in MATLAB (The Math-
Works, Natick, MA, USA). A region of interest (ROI) was selected
in the contrast-enhanced T1-weighted image that included the
sonicated area of the retina and the vitreous humor. The mean
signal intensity in the ROI was found as a function of time for the
time-series of images. The percent signal intensity enhancement
was found by normalizing the measurements to those made in an
image obtained before Gd-DTPA administration. The enhance-
ment in the sonicated areas was compared to that measurements
obtained in a similar region of interest selected in control (non-
sonicated) animals using an unpaired two-tailed t-test. Values of
p,0.05 were considered statistically significant.
Results
MRI analysis of BRB disruption
In each animal, a time-series of contrast-enhanced T1-weighted
images of the eye was obtained to evaluate the integrity of the BRB
(Fig. 2). No signal enhancement suggesting any Gd-DTPA leakage
into the retina or vitreous humor was observed in non-sonicated
(control) animals. Only those animals that received FUS and
microbubbles resulted in detectable signal enhancement.
Figure 2 shows the results of a typical experiment with the
highest FUS pressure amplitude tested (1.1 MPa). The BRB
disruption was observed initially as signal enhancement in the
retina at the sonicated locations (arrows in Fig. 2B). At later times
enhancement was observed in the vitreous humor as the Gd-
DTPA diffused out from the retina. Ultimately the signal in entire
vitreous humor appeared to be enhanced. The mean signal
intensity at the ROI indicated by the dotted line in Fig. 2B
increased by over 50% compared to the baseline, while the signal
intensity increase at control eye was near zero (Fig. 2D). The
sonicated eye was imaged again 3.5 h following the last sonication
with the second MRI contrast injection (Fig. 2C). Low-level BRB
disruption was still observed but the level was substantially less
compared to the first MRI contrast injection. The maximum
signal intensity enhancement at 3.5 h was only around 15%
compared to the baseline (Fig. 2E).
MRI contrast enhancement in the retina and vitreous humor
similar to that seen in Fig. 2 was observed after FUS at the three
PRFP amplitude tested: 0.81 (N=6), 0.88 (N=4), and 1.1 MPa
(N=6), in each of the sonicated eyes (N=16) and in none of the
controls (N=4). The maximum signal enhancement increase was
the largest after sonication at 1.1 MPa. Sonications at 0.81 and
0.88 MPa produced similar levels of enhancement (Fig. 3). Signal
Figure 2. BRB disruption in the rat eye after sonication with microbubbles at five overlapping targets centered on the optic nerve
head. (A–C) Time-series of sagittal contrast-enhanced T1-weighted images of a rat eye acquired at 5 min intervals after an IV injection of MRI
contrast agent (Gd-DTPA). (A) Control eye. (B) Gd-DTPA injection 10 min after the last sonication. (C) The second Gd-DTPA injection 3.5 h after the
sonications to examine the recovery of the BRB. (D–E) The normalized signal intensity (SI) increase (spatial averaged mean 6 S.D.) due to
extravasation of Gd-DTPA was measured as a function of time in a region of interest (dotted line) that included the sonicated retina and the vitreous.
In C and E, the BRB was not fully recovered at 3.5 h. The ultrasound beam propagated from right to left with respect to these images. The peak
rarefactional pressure amplitude for sonications was 1.1 MPa with 20 ml/kg microbubbles USCA (Definity). Scale bars in A–C: 2 mm.
doi:10.1371/journal.pone.0042754.g002
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than those at control group at each time point (p,0.05). At the
lowest pressure amplitude tested (0.81 MPa), the BRB appeared to
be restored in three animals imaged 3 h after sonication with the
second injection of MRI contrast agent (Fig. 4). In these animals, a
mean enhancement level of 30% above baseline was achieved
after the first Gd-DTPA injection was administered. After the
second injection 3 h later, the mean enhancement level was less
than 5% above the baseline and was not significantly different
(p.0.05) compared to what was achieved in the control animals.
Histology analysis
Histological examination was performed on three sonicated eyes
which showed the largest effect on contrast enhanced T1-weighted
MRI; one for each of the three pressure amplitudes tested and one
control eye. At 0.81 and 0.88 MPa, the retina in the sonicated
region appeared to be generally unaffected in the H&E-stained
sections except for few tiny (,100 mm) clusters of extravasated
erythrocytes (petechaie) found in the nuclear layers of the retina.
Other structures that were exposed to FUS along the beam path
(choroid, cornea, iris, lens, optic nerve) appeared normal. More
extensive damage such as more petechaie and retinitis were
observed after sonication at 1.1 MPa. Figures 5 shows retina from
the control eye (Fig. 5 A–B) and the largest effects found in each
sonicated eye on histological examination (Fig. 5 C–H).
Discussion
This study demonstrated that appropriately powered FUS
combined with circulating microbubbles can induce a transient
and reversible disruption of the BRB, resulting in extravasation of
a systemically injected MRI contrast agent into the retina and
vitreous. By combining the BRB disruption and systemic injection,
this method could be used to deliver therapeutic agents or imaging
probes which normally do not enter the retina. The BRB appeared
to be restored within a few hours, which could provide a good
time-window for ocular drug delivery while avoiding unwanted
effects that may result from long-term BRB disruption. Gd-DTPA
was observed to leak into the vitreous humor after sonication, and
over 25 min, this enhancement covered its entire extent within the
vitreous humor. Any agent that leaks out of the retinal blood
vessels using this technology would thus potentially be delivered to
the entire retina. Presumably the retinal tissue where the BRB was
Figure 3. The average normalized signal intensity (SI) change
measured in a time-series of contrast enhanced T1-weighted
images for all animals (mean ± S.D.). The horizontal axis shows the
interval after Gd-DTPA injection, which was administered 10 min after
the last sonication in each eye. The measurements were obtained in a
region of interest that included the sonicated portion of the retina and
the vitreous humor. The pressure amplitudes of these sonications were:
0.81 (N=6), 0.88 (N=4), 1.1 MPa (N=6) for sonicated eyes and 0 MPa
(n=4) for the control eyes. The SI increase in the sonicated eyes was
significantly larger than that in the controls at every time point (*
p,0.05; ** p,0.01).
doi:10.1371/journal.pone.0042754.g003
Figure 4. Recovery of the BRB 3 h after sonication at 0.81 MPa.
The signal intensity (SI) increase measured in a ROI that included the
retina and the vitreous humor is plotted as a function of time after two
injections of MR contrast agent (Gd-DTPA). After the first injection
(10 min after the last sonication), the SI increase was significantly larger
(* p,0.05; ** p,0.01) than the controls for every point in the time-
series. After the second injection (3 h after sonication), the SI changes
were not significantly different than the controls (p.0.05) at any time
point. Data shown are the average SI increase (mean 6 S.D.) for three
sonicated eyes and four controls.
Figure 5. Microphotographs of H&E-stained sections from
representative examples from each experimental group
(Table 1). Images on the right are high-magnification views of the
boxed regions shown on the left. (A–B) Non-sonicated (control) eye.
(C–H) The largest effects found on histological examination in each BRB
disrupted eye at increasing acoustical pressure amplitudes: (C–D)
0.81 MPa; (E–F) 0.88 MPa; (G–H) 1.1 MPa. At 0.81–0.88 MPa, the retina
and other ocular structures appeared mostly normal except for tiny
petechaie found in the nuclear layers of the retina. At 1.1 MPa, more
extensive petechaie were found. The animals were sacrificed 24 h after
the sonications. The retinal separations evident in these images were
artifacts that occurred during formalin fixation and tissue preparation.
Scale bars: 100 mm.
doi:10.1371/journal.pone.0042754.g005
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drug via the vitreous, but this would need to be verified.
A number of methods have been evaluated to overcome the
BBB for drug delivery, including intraarterial infusion of a
hyperosmotic solution such as mannitol to diffusely disrupt the
barrier, or modifying or encapsulating drugs to enable their
transport across the brain endothelium [28]. In principle, similar
techniques could be used to deliver drugs to the retina [29].
However, those methods would be either invasive, non-targeted,
or require the development of new drug formulations, which may
change the drug’s pharmacokinetic properties. Such strategies may
also result in the delivery of agents to the CNS. In contrast, FUS
combined with microbubble is noninvasive, localized, repeatable,
and could utilize already developed pharmacological agents
without modification of drug properties.
FUS devices designed to target the retina for drug delivery
would be relatively simple to construct compared to other targets
(particularly the brain), due to the eye’s superficial location. The
therapeutic use of FUS in the eye has a long history, with prior
studies investigating it for a variety of applications including
treatments for glaucoma and ocular tumors and for transcorneal
drug delivery [30,31,32,33,34,35,36,37,38,39]. In fact, the first
FDA-approved high-intensity focused ultrasound device was for
applications in the eye [40]. This prior experience can be useful
the development of devices for use in humans and for clinical
translation.
There is less prior experience with microbubble-enhanced
ultrasound in the eye. While investigators have utilized contrast-
enhanced ultrasonography in the eye [41,42], and others have
injected microbubbles into the vitreous along with viral vectors or
siRNA for retinal delivery via sonoporation [43,44], we are not
aware of prior work with circulating microbubbles and sonication
parameters similar to those used in the present study. One study
by Hirokawa et al. [45] investigated bioeffects produced in the
retina after ultrasound imaging with a microbubble USCA using
fundus angiography. In that work, which used a 2 MHz
transducer to sonicate the rabbit eye, increased retinal permeabil-
ity was noted in one of five animals (peak rarefactional focal
pressure (PRFP): 2.0 MPa), and vasoconstriction was noted in four
of five cases. In our current study, we achieved an increase in
retinal permeability at substantially lower PRFP amplitudes (0.81–
1.1 MPa). While it is difficult to directly compare our findings to
that work because of the multitude of differences in the exposure
conditions (frequency, burst length, pulse repetition frequency,
USCA dose, etc.), the disparate outcomes are generally consistent
with what has been observed in the brain. Experiments testing
brain sonications have found that higher pressure amplitude is
needed to induce BBB disruption when the ultrasonic frequency is
increased [46] and when the burst length decreased [47]. Others
have also shown that vasoconstriction can occur during sonication
in the brain with FUS and microbubbles [48]. Thus, while more
work is needed to evaluate the bioeffects observed in the retina
after sonication with microbubbles, we might expect that prior
results achieved in the brain may point to how BRB disruption can
be optimized.
If the vascular response to FUS and microbubbles in the retina
and the brain are indeed similar, we might expect that BRB
disruption could be achieved at lower amplitudes than were tested
here. Previous work in rabbits has shown that the threshold for
BBB disruption at 690 kHz is between 0.3–0.4 MPa [46], and that
significant petechaie and mild parenchymal damage occurs at
0.8 MPa [19]. Here, we used higher PRFP amplitudes (estimated
to be 0.78–1.06 MPa at the retina), double the USCA dose, and a
twice the sonication duration than was used in the brain studies
[46]. These parameters were used to achieve signal intensity
increases in contrast MRI similar to what has been observed in the
brain.
Detecting MRI contrast at a lower level with our MRI protocol
may be challenging. The vascular density in the retina is lower
than in the brain, and the amount of tracer that leaks into the
extravascular space will be smaller. Furthermore, the retinal
thickness in the rat (,200 mm) is a small fraction of the voxel
dimensions in our MR imaging, which will lead to volume-
averaging and reduced sensitivity to low-level BRB disruption.
While volume averaging errors will be reduced as Gd-DTPA
diffuses into the vitreous, the concentration in the vitreous may be
small for low-level BRB disruption. Future work should test more
sensitive methods to investigate the threshold for BRB disruption,
such as optical techniques using fluorescent tracers or high-field
MRI using a small eye coil.
Being able to achieve BRB disruption at lower exposure levels
may reduce the risk for side effects. While we did not see retinal
damage at the two lower exposure levels (0.81 and 0.88 MPa), we
did find tiny petechaie at a few locations in each eye. We sonicated
five locations in each eye; most of the retina was sonicated and
demonstrated BRB disruption. The fact that petechaie were
detected in only few focal areas (Fig. 5) suggests that perhaps we
were operating just above the threshold for inertial cavitation and
that BRB disruption without these petechaie could be achieved at
lower PRFP amplitudes than were used here.
The risk for side effects may also be reduced using a transducer
that produces a smaller focal region, which could be achieved
using a higher ultrasound frequency. We used a low frequency
(690 kHz) for this initial work based on parameters that we have
been using for BBB disruption. In the brain, use of a lower
frequency appears to pose less risk for petechaie than higher values
closer to the resonant frequency of the microbubbles [46]. A lower
frequency also will be less affected by the lens, which may distort
the ultrasound field. However, low frequency ultrasound may not
be ideal for retinal sonications due to the size of the focal region
and the potential for unwanted effects to surrounding tissues.
Future work is needed to optimize the FUS device and the
sonication parameters for this application and to evaluate the
sonication effects. In particular, it may be desirable to avoid
sonication through the lens. For humans and other animals with
larger eyes, this could be achieved using a transducer with a
toroidal geometry.
Outlook
This feasibility study was limited, and additional future work on
this technique is needed to advance this technique. We only
evaluated a relatively narrow range of exposure conditions, and
our sonication system and imaging were not optimized. A broader
range of parameters should be evaluated with devices designed for
ocular sonication to optimize the exposures and minimize the risk
for side effects. We likely had some variation from target-to-target
in the actual PRFP amplitude at the retina, as we did not take into
account beam aberration induced by the lens, clipping of the FUS
beam by the bone in the eye socket, and reflections from the bone
behind the eye. More reliable exposures might be achieved by
recording acoustic emissions to evaluate the microbubble dynam-
ics and control the sonication system [49] and by integrating a
fundus camera into the FUS system to monitor the retina in real-
time. We also only evaluated short-term histological effects of the
sonications, and future work should evaluate whether the
procedure induces any functional changes. For example, electro-
retinograms (ERG) can be performed after the sonications to
evaluate the effects on retinal function. Finally, the safety of
Targeted and Reversible BRBD
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evaluated. Delivery of therapeutic agents such as anti-VEGF
antibodies, genes, or siRNA for degenerative diseases such as age-
related macular degeneration could be applications with a good
opportunity to improve therapeutic outcomes.
Despite the limitations of this study, these results are a major
step forward in producing a noninvasive alternative to ocular drug
delivery for treatment of retinal disorders such as age-related
macular degeneration, diabetic retinopathy and retinitis pigmen-
tosa. Retinal tumors may also benefit from this approach through
the delivery of agents to infiltrating cancer cells that are protected
by the BRB and by increasing drug delivery to the vascular part of
the tumor. In addition, this technology would provide an
alternative for patients who cannot tolerate intravitreal injection
due to a risk of retinal detachment or increased intraocular
pressure.
Conclusion
In conclusion, these experiments have shown that FUS and
microbubbles can induce a temporary disruption of the BRB in
rats. Using FUS exposure parameters similar to those used
previously to disrupt the BBB, we found that we could deliver an
MRI contrast agent that normally does not extravasate to the
retina and the vitreous humor due to the presence of the BRB. No
significant retinal damage was found in histology at the two lower
acoustic pressure amplitudes tested, and the barrier was found to
be restored 3 h after sonication. This technique could provide a
noninvasive method to deliver drugs to the retina, avoiding the
need for intraocular injections.
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